Generating Insights and Understanding of Antibiotic Resistance Development

Experts on antibiotic-resistant bacteria might be interested in two new funding opportunity announcements (FOAs): Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01, Clinical Trial Not Allowed) and (R21, Clinical Trial Not Allowed).

Through these FOAs, you will have the opportunity to advance critical research areas from the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB). One of the goals of CARB is to advance basic and applied research and development for new antibiotics, other therapeutics, and vaccines. A related objective is to increase research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

NIAID will give priority to:

  • Clinical research focused on the microbiome of human cohorts at high risk for acquiring drug-resistant infections
  • Approaches to studying human-associated microbial communities and the mechanisms that generate colonization resistance or promote emergence of drug-resistant bacteria
  • Characterizing and identifying combinations of existing antimicrobials to improve therapy for infections caused by multidrug-resistant Gram-negative bacteria by leveraging model systems or existing cohorts

Examples of research topics include:

  • Preventing the dissemination of carbapenem-resistant Enterobacteriaceae 
  • Measuring changes and patterns in the microbiota relative to patient outcomes
  • Identifying longitudinal sampling of the human microbiota focusing on high-risk cohorts for temporal and statistical associations
  • Distinguishing mechanisms by which the host microbiota confers resistance to colonization by pathogenic bacteria

See a comprehensive list of examples of research topics in the FOAs linked above. 

Nonresponsive Applications Will Not Be Reviewed

Do not propose applications that focus on HIV/SIV/AIDS. If you do, NIAID will deem your application nonresponsive and therefore not review it.

Award and Deadline Details

For the R21, your combined budget for direct costs for the two-year project period may not exceed $275,000. You cannot request more than $200,000 in any single year.

Your budget for an R01 application is not limited but must reflect the actual needs of your proposed project—however, if you request $500,000 or more in direct costs in any year, you must seek approval from an NIAID program officer at least six or more weeks before applying and include an acceptance letter with your application. The maximum R01 project period is five years.

The application deadlines follow NIH’s Standard Due Dates. For example, the next deadline for a new R01 application is June 5, 2018, and for an R21 is June 16, 2018.

Contact and Additional Information

Find complete details in the FOAs linked above, in addition to instructions described in the SF 424 (R&R) Application Guide.

Direct your NIAID-related scientific/research questions to Dr. Ryan Ranallo.

Content last reviewed on April 17, 2018

Browse all Articles